21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer

Introduction: It is still controversial whether post-mastectomy radiotherapy (PMRT) is necessary for women with T1-2 N1mic ER-positive HER2-negative breast cancer. The 21-gene recurrence score (RS) assay has been validated in T1-2 N1 breast cancer to be prognostic of locoregional recurrence (LRR) an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Zhang, Wen-Wen, Tong, Qin, Sun, Jia-Yuan, Hua, Xin, Long, Zhi-Qing, Deng, Jia-Peng, Dong, Yong, Li, Feng-Yan, He, Zhen-Yu, Wu, San-Gang, Lin, Huan-Xin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2019
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477026/
https://ncbi.nlm.nih.gov/pubmed/31041190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00270
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller